Vericel Corp. (VCEL)

[Lunacy_John Galt]

Companies are devastated by sub-optimal trial designs all the time, I imagine it will be very difficult for them to overcome this. I believe they need $ as well. It’s difficult approaching a health care provider with trial data, while having to say “but if it was done this way it wouldn’t have failed.”

“In the modified Intent to Treat (mITT) population (which excludes those patients who were randomized but not treated with NeoCart)”